Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology

Open Access 20-11-2023 | Aneurysm | Review

Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management

Authors: Jiangtao Li, Jing Fang, Yani Liu, Xiang Wei

Published in: Clinical Research in Cardiology

Login to get access

Abstract

Since the first description of apical hypertrophic cardiomyopathy (ApHCM) in 1976, contrasting information from all over the world has emerged regarding the natural history of the disease. However, the recommended guidelines on hypertrophic cardiomyopathy (HCM) pay a cursory reference to ApHCM, without ApHCM-specific recommendations to guide the diagnosis and management. In addition, cardiologists may not be aware of certain aspects that are specific to this disease subtype, and a robust understanding of specific disease features can facilitate recognition and timely diagnosis. Therefore, the review covers the incidence, pathogenesis, and characteristics of ApHCM and imaging methods. Echocardiography and cardiovascular magnetic resonance imaging (CMR) are the most commonly used imaging methods. Moreover, this review presents the management strategies of this heterogeneous clinical entity. In this review, we introduce a novel transapical beating-heart septal myectomy procedure for ApHCM patients with a promising short-time result.

Graphical abstract

Literature
1.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 76(25):e159–e240 PubMedCrossRef
2.
Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779 CrossRef
3.
Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF et al (2019) Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol 74(19):2333–2345 PubMedPubMedCentralCrossRef
4.
Yin Y, Hu W, Zhang L, Wu D, Yang C, Ye X (2022) Clinical, echocardiographic and cardiac MRI predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 38(3):643–651 PubMedCrossRef
5.
Kubo T, Kitaoka H, Okawa M, Hirota T, Hoshikawa E, Hayato K et al (2009) Clinical profiles of hypertrophic cardiomyopathy with apical phenotype–comparison of pure-apical form and distal-dominant form. Circ J 73(12):2330–2336 PubMedCrossRef
6.
Moon J, Shim CY, Ha JW, Cho IJ, Kang MK, Yang WI et al (2011) Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Am J Cardiol 108(11):1614–1619 PubMedCrossRef
7.
Klarich KW, Attenhofer Jost CH, Binder J, Connolly HM, Scott CG, Freeman WK et al (2013) Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol 111(12):1784–1791 PubMedCrossRef
8.
Maron BJ, Maron MS, Semsarian C (2012) Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 60(8):705–715 PubMedCrossRef
9.
10.
Mosqueira D, Smith JGW, Bhagwan JR, Denning C (2019) Modeling hypertrophic cardiomyopathy: mechanistic insights and pharmacological intervention. Trends Mol Med 25(9):775–790 PubMedCrossRef
11.
Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A et al (2010) Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 53(5):261–267 PubMedCrossRef
12.
Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749–770 PubMedPubMedCentralCrossRef
13.
Moro E, D’Angelo G, Nicolosi GL, Mimo R, Zanuttini D (1995) Long-term evaluation of patients with apical hypertrophic cardiomyopathy Correlation between quantitative echocardiographic assessment of apical hypertrophy and clinical-electrocardiographic findings. Eur Heart J 16(2):210–217 PubMedCrossRef
14.
Monserrat L, Hermida-Prieto M, Fernandez X, Rodriguez I, Dumont C, Cazon L et al (2007) Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Eur Heart J 28(16):1953–1961 PubMedCrossRef
15.
Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, Ho CY et al (2005) Gene mutations in apical hypertrophic cardiomyopathy. Circulation 112(18):2805–2811 PubMedCrossRef
16.
Towe EC, Bos JM, Ommen SR, Gersh BJ, Ackerman MJ (2015) Genotype–phenotype correlations in apical variant hypertrophic cardiomyopathy. Congenit Heart Dis 10(3):E139–E145 PubMedCrossRef
17.
Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P et al (2020) Apical hypertrophic cardiomyopathy: the variant less known. J Am Heart Assoc 9(5):e015294 PubMedPubMedCentralCrossRef
18.
Flett AS, Maestrini V, Milliken D, Fontana M, Treibel TA, Harb R et al (2015) Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. Int J Cardiol 183:143–148 PubMedPubMedCentralCrossRef
19.
Wu B, Lu M, Zhang Y, Song B, Ling J, Huang J et al (2017) CMR assessment of the left ventricle apical morphology in subjects with unexplainable giant T-wave inversion and without apical wall thickness >/=15 mm. Eur Heart J Cardiovasc Imaging 18(2):186–194 PubMedCrossRef
20.
Kim H, Park JH, Won KB, Yoon HJ, Park HS, Cho YK et al (2016) Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy. Heart 102(15):1215–1220 PubMedCrossRef
21.
Matsubara K, Nakamura T, Kuribayashi T, Azuma A, Nakagawa M (2003) Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy. J Am Coll Cardiol 42(2):288–295 PubMedCrossRef
22.
Jan MF, Todaro MC, Oreto L, Tajik AJ (2016) Apical hypertrophic cardiomyopathy: present status. Int J Cardiol 222:745–759 PubMedCrossRef
23.
Sherrid MV, Bernard S, Tripathi N, Patel Y, Modi V, Axel L et al (2023) Apical aneurysms and mid-left ventricular obstruction in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 16(5):591–605 PubMedCrossRef
24.
Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S et al (2011) Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 57(23):2346–2355 PubMedCrossRef
25.
Kim EK, Lee SC, Hwang JW, Chang SA, Park SJ, On YK et al (2016) Differences in apical and non-apical types of hypertrophic cardiomyopathy: a prospective analysis of clinical, echocardiographic, and cardiac magnetic resonance findings and outcome from 350 patients. Eur Heart J Cardiovasc Imaging 17(6):678–686 PubMedCrossRef
26.
Kao YC, Lee MF, Mao CT, Chen WS, Yang NI, Cherng WJ et al (2013) Differences of left ventricular systolic deformation in hypertensive patients with and without apical hypertrophic cardiomyopathy. Cardiovasc Ultrasound 11:40 PubMedPubMedCentralCrossRef
27.
Chen CC, Lei MH, Hsu YC, Chung SL, Sung YJ (2011) Apical hypertrophic cardiomyopathy: correlations between echocardiographic parameters, angiographic left ventricular morphology, and clinical outcomes. Clin Cardiol 34(4):233–238 PubMedPubMedCentralCrossRef
28.
Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS et al (2017) Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol 69(7):761–773 PubMedCrossRef
29.
Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH et al (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915–1928 PubMedCrossRef
30.
Hughes RK, Augusto JB, Knott K, Davies R, Shiwani H, Seraphim A et al (2023) Apical ischemia is a universal feature of apical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 16(3):e014907 PubMedPubMedCentral
31.
Yang K, Song YY, Chen XY, Wang JX, Li L, Yin G et al (2020) Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. Eur Heart J Cardiovasc Imaging 21(12):1341–1350 PubMedCrossRef
32.
Yang K, Yu SQ, Chen XY, Song YY, Yang SJ, Cui C et al (2023) Apical aneurysm formation in apical hypertrophic cardiomyopathy: Pilot study with cardiac magnetic resonance. Int J Cardiol 371:480–485 PubMedCrossRef
33.
Singam NSV, Stoddard MF (2019) The evolution of apical hypertrophic cardiomyopathy: development of mid-ventricular obstruction and apical aneurysm 11 years after initial diagnosis. Echocardiography 36(5):987–991 PubMedCrossRef
34.
Binder J, Attenhofer Jost CH, Klarich KW, Connolly HM, Tajik AJ, Scott CG et al (2011) Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. J Am Soc Echocardiogr 24(7):775–781 PubMedCrossRef
35.
Paluszkiewicz J, Krasinska B, Milting H, Gummert J, Pyda M (2018) Apical hypertrophic cardiomyopathy: diagnosis, medical and surgical treatment. Kardiochir Torakochirurgia Pol 15(4):246–253 PubMedPubMedCentral
36.
Yan L, Wang Z, Xu Z, Li Y, Tao Y, Fan C (2012) Two hundred eight patients with apical hypertrophic cardiomyopathy in China: clinical feature, prognosis, and comparison of pure and mixed forms. Clin Cardiol 35(2):101–106 PubMedCrossRef
37.
38.
Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED et al (2002) Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 39(4):638–645 PubMedCrossRef
39.
Shin DG, Son JW, Park JY, Choi JW, Ryu SK (2015) Impact of coronary artery anatomy on clinical course and prognosis in apical hypertrophic cardiomyopathy: analysis of coronary angiography and computed tomography. Korean Circ J 45(1):38–43 PubMedPubMedCentralCrossRef
40.
Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F et al (1979) Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 44(3):401–412 PubMedCrossRef
41.
Koga Y, Katoh A, Matsuyama K, Ikeda H, Hiyamuta K, Toshima H et al (1995) Disappearance of giant negative T waves in patients with the Japanese form of apical hypertrophy. J Am Coll Cardiol 26(7):1672–1678 PubMedCrossRef
42.
Chen X, Dong JZ, Du X, Wu JH, Yu RH, Long DY et al (2018) Long-term outcome of catheter ablation for atrial fibrillation in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 29(7):951–957 PubMedCrossRef
43.
Tower-Rader A, Kramer CM, Neubauer S, Nagueh SF, Desai MY (2020) Multimodality imaging in hypertrophic cardiomyopathy for risk stratification. Circ Cardiovasc Imaging 13(2):e009026 PubMedPubMedCentralCrossRef
44.
Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A et al (2022) Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the american society of echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 35(6):533–569 PubMedCrossRef
45.
Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A et al (2015) Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 16(3):280 PubMedCrossRef
46.
Louie EK, Maron BJ (1987) Apical hypertrophic cardiomyopathy: clinical and two-dimensional echocardiographic assessment. Ann Intern Med 106(5):663–670 PubMedCrossRef
47.
Webb JG, Sasson Z, Rakowski H, Liu P, Wigle ED (1990) Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol 15(1):83–90 PubMedCrossRef
48.
Huang G, Fadl SA, Sukhotski S, Matesan M (2020) Apical variant hypertrophic cardiomyopathy “multimodality imaging evaluation.” Int J Cardiovasc Imaging 36(3):553–561 PubMedCrossRef
49.
Unlu S, Duchenne J, Mirea O, Pagourelias ED, Bezy S, Cvijic M et al (2020) Impact of apical foreshortening on deformation measurements: a report from the EACVI-ASE Strain Standardization Task Force. Eur Heart J Cardiovasc Imaging 21(3):337–343 PubMed
50.
Chang SA, Kim HK, Kim DH, Kim JC, Kim YJ, Kim HC et al (2010) Left ventricular twist mechanics in patients with apical hypertrophic cardiomyopathy: assessment with 2D speckle tracking echocardiography. Heart 96(1):49–55 PubMedCrossRef
51.
Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL et al (2017) Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 18(11):1205–1205af PubMedCrossRef
52.
Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y et al (2018) Cardiac MR imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci 17(2):120–131 PubMedPubMedCentralCrossRef
53.
Kebed KY, Al Adham RI, Bishu K, Askew JW, Klarich KW, Araoz PA et al (2014) Evaluation of apical subtype of hypertrophic cardiomyopathy using cardiac magnetic resonance imaging with gadolinium enhancement. Am J Cardiol 114(5):777–782 PubMedCrossRef
54.
55.
To AC, Dhillon A, Desai MY (2011) Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 4(10):1123–1137 PubMedCrossRef
56.
Narula J, Chandrashekhar Y, Ahmadi A, Abbara S, Berman DS, Blankstein R et al (2021) SCCT 2021 Expert Consensus Document on coronary computed tomographic angiography: a report of the society of cardiovascular computed tomography. J Cardiovasc Comput Tomogr 15(3):192–217 PubMedCrossRef
57.
Williams TJ, Manghat NE, McKay-Ferguson A, Ring NJ, Morgan-Hughes GJ, Roobottom CA (2008) Cardiomyopathy: appearances on ECG-gated 64-detector row computed tomography. Clin Radiol 63(4):464–474 PubMedCrossRef
58.
Mowatt G, Cook JA, Hillis GS, Walker S, Fraser C, Jia X et al (2008) 64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. Heart 94(11):1386–1393 PubMedCrossRef
59.
Goldstein JA, Gallagher MJ, O’Neill WW, Ross MA, O’Neil BJ, Raff GL (2007) A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 49(8):863–871 PubMedCrossRef
60.
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503–3626 PubMedCrossRef
61.
Maron BJ (2018) Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 379(20):1977 PubMed
62.
Authors/Task Force M, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A et al (2022) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4–131 CrossRef
63.
Shimada YJ, Passeri JJ, Baggish AL, O’Callaghan C, Lowry PA, Yannekis G et al (2013) Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail 1(6):480–487 PubMedPubMedCentralCrossRef
64.
Axelsson A, Iversen K, Vejlstrup N, Ho CY, Havndrup O, Kofoed KF et al (2016) Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Heart 102(4):285–291 PubMedCrossRef
65.
Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L et al (2015) Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 3(2):123–131 PubMedCrossRef
66.
Grillo MP, Erve JCL, Dick R, Driscoll JP, Haste N, Markova S et al (2019) In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica 49(6):718–733 PubMedCrossRef
67.
Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM (2017) A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem 292(40):16571–16577 PubMedPubMedCentralCrossRef
68.
Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H et al (2018) Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA 115(35):E8143–E8152 PubMedPubMedCentralCrossRef
69.
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM et al (2020) Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649–2660 PubMedCrossRef
70.
Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S et al (2021) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10293):2467–2475 PubMedCrossRef
71.
Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P et al (2019) Enhanced American College of Cardiology/American Heart Association Strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol 4(7):644–657 PubMedPubMedCentralCrossRef
72.
Tengiz I, Ercan E, Alioglu E, Turk UO (2006) Percutaneous septal ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. BMC Cardiovasc Disord 6:15 PubMedPubMedCentralCrossRef
73.
Inada K, Seiler J, Roberts-Thomson KC, Steven D, Rosman J, John RM et al (2011) Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 22(1):41–48 PubMedCrossRef
74.
Schaff HV, Brown ML, Dearani JA, Abel MD, Ommen SR, Sorajja P et al (2010) Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 139(3):634–640 PubMedCrossRef
75.
Said SM, Schaff HV (2013) Surgical treatment of hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg 25(4):300–309 PubMedCrossRef
76.
Hang D, Schaff HV, Ommen SR, Dearani JA, Nishimura RA (2018) Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 155(5):2096–2102 PubMedCrossRef
77.
Nguyen A, Schaff HV, Nishimura RA, Geske JB, Dearani JA, King KS et al (2019) Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg 159(1):145–152 PubMedCrossRef
78.
Fang J, Liu Y, Zhu Y, Li R, Wang R, Wang DW et al (2023) First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 82(7):575–586 PubMedCrossRef
79.
Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ (2003) Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 92(10):1183–1186 PubMedCrossRef
80.
Yang HS, Song JK, Song JM, Kang DH, Lee CW, Hong MK et al (2005) Comparison of the clinical features of apical hypertrophic cardiomyopathy versus asymmetric septal hypertrophy in Korea. Korean J Intern Med 20(2):111–115 PubMedPubMedCentralCrossRef
81.
Kim SH, Kim SO, Han S, Hwang KW, Lee CW, Nam GB et al (2013) Long-term comparison of apical versus asymmetric hypertrophic cardiomyopathy. Int Heart J 54(4):207–211 PubMedCrossRef
82.
Klarich KW, AttenhoferJost CH, Binder J, Connolly HM, Scott CG, Freeman WK et al (2013) Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol 111(12):1784–1791 PubMedCrossRef
83.
Cai C, Duan FJ, Yang YJ, Guo XY, Liu YL, Liu YQ et al (2014) Comparison of the prevalence, clinical features, and long-term outcomes of midventricular hypertrophy vs apical phenotype in patients with hypertrophic cardiomyopathy. Can J Cardiol 30(4):441–447 PubMedCrossRef
84.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 142(25):e533–e557 PubMed
85.
Li J, Zhang J, Shi Y, Sievert H, Taub CC, Bertog S et al (2023) Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation. Heart 109(4):289–296 PubMedCrossRef
86.
Subramanian M, Atreya AR, Yalagudri SD, Shekar PV, Saggu DK, Narasimhan C (2022) Catheter ablation for ventricular arrhythmias in hypertrophic cardiomyopathy. Card Electrophysiol Clin 14(4):693–699 PubMedCrossRef
87.
Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE et al (2017) Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg 6(4):353–363 PubMedPubMedCentralCrossRef
Metadata
Title
Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management
Authors
Jiangtao Li
Jing Fang
Yani Liu
Xiang Wei
Publication date
20-11-2023
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02328-8
Webinar | 16-05-2023 | 17:30 (CET)

Keynote Webinar | Spotlight on Cardio-Oncology

Watch now

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández
Image Credits